Organization (Hospital)
University of Vermont Medical Center
ClinicalTrials.gov lists University of Vermont Medical Center as lead sponsor of 43 trials. It has 12 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs. 3 trials are registered to start in 2027 or later.
This page covers University of Vermont Medical Center: 43 lead-sponsored trials and 1 legal-entity registration.
Disease areas (65)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Insulin Resistance | 3 |
| Pain | 3 |
| Substance-Related Disorders | 3 |
| Brain Neoplasms | 2 |
| Breast Neoplasms | 2 |
Showing 5 of 65 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 7 |
| 2024 | 2 |
| 2023 | 5 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 21 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; 8 of 10 predicted trials reach the 36-month horizon; registered median of 24 months across 20 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Active Surveillance (study visit Day 1, Day 2 and Day 7) | Head and Neck Neoplasms | Phase 2 | 1 |
| Hypofractionated Radiation Therapy | Anus Neoplasms | Phase 2 | 1 |
| Hypofractionated Radiation Therapy | Rectal Neoplasms | Phase 2 | 1 |
| Hypofractionated Radiation Therapy | Colorectal Neoplasms | Phase 2 | 1 |
| Active Surveillance (study visit Day 1, Day 2 and Day 7) | Brain Neoplasms | Phase 2 | 1 |
Showing 5 of 12 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Intravenous Lidocaine Infusion | 1 |
| Remifentanil | 1 |
| Pyridostigmine | 1 |
| Apixaban | 1 |
| Varenicline | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 29% hit target (n=7) | 43% on time (n=7) |
Journals published in (107)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesiology | 8 |
| Journal of vascular surgery | 8 |
| The American journal of clinical nutrition | 6 |
| Nutrients | 5 |
| The Cochrane database of systematic reviews | 5 |
Showing 5 of 107 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 6 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Sinai Health System | Co sponsors trial with | 1 |
| Versiti Blood Health | Co sponsors trial with | 1 |
| King Fahad Medical City | Co sponsors trial with | 1 |
| Peter Lougheed Centre | Co sponsors trial with | 1 |
| BJC HealthCare | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (63)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2028-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 63 events.
CLIA clinical laboratory certificates (5)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| UNIVERSITY OF VERMONT MEDICAL CENTER | Certificate of accreditation | Active |
| UNIVERSITY OF VERMONT MEDICAL CENTER | Certificate for PPM procedures | Active |
| UNIVERSITY OF VERMONT MEDICAL CENTER | Certificate of accreditation | Terminated |
| UNIVERSITY OF VERMONT MEDICAL CENTER | Certificate of accreditation | Terminated |
| UNIVERSITY OF VERMONT MEDICAL CENTER | Certificate for PPM procedures | Terminated |
Biomarker capability evidence (32)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| CD274 | Trial sponsor | Named in trial inclusion criteria |
| CTLA4 | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 32 evidence rows.
Biomarkers this organization publishes on (121)
Shown in this order: most publications first.
Showing 5 of 121 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.